Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Yunnan Biopharmaceutical, received approval from China's Ministry of Agriculture and Rural Affairs for a cat vaccine, according to a Wednesday disclosure on the Shanghai Stock Exchange.
The certificate for the triple inactivated vaccine for feline rhinotracheitis, calicivirus disease, and panleukopenia is valid until Sept. 1, 2026, the pharmaceutical company said.
The company's shares rose 1% in recent trade.
Price (RMB): ¥8.31, Change: ¥+0.080, Percent Change: +0.97%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments